Celldex Therapeutics, Inc. (CLDX)

Over the past six months, Celldex reported positive clinical data for Barzolvolimab in Eosinophilic Esophagitis and chronic spontaneous urticaria, and for CDX-622 in a Phase 1 trial. Celldex reported its Third Quarter 2025 financial results in November 2025, noting a net loss of $67.0 million. Teri Lawver was appointed as Senior Vice President, Chief Commercial Officer. Celldex initiated a global registrational Phase 3 program for Barzolvolimab in Cold Urticaria and Symptomatic Dermographism. Analyst sentiment remains largely bullish, with a consensus rating of "Moderate Buy". The stock has experienced volatility, with a 52-week range between approximately $14.40 and $30.50.

As a clinical-stage biopharmaceutical company, Celldex Therapeutics, Inc. does not currently have commercialized products or services. Therefore, there is no information available regarding demand seasonality for its products or services.

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. They specialize in therapeutic antibodies and are dedicated to tackling conditions with limited existing treatments, supported by in-house capabilities for discovery and development. Their major product candidates include Barzolvolimab (CDX-0159) and CDX-622. As a clinical-stage entity, Celldex's financial performance reflects significant research and development outlays rather than immediate profit generation.

Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey, United States. As a clinical-stage biopharmaceutical company, information regarding a broader global geographic footprint for commercial operations or product sales is not applicable at this stage of its development.

Celldex Therapeutics generally holds a positive brand reputation, particularly among analysts, due to its innovative pipeline and promising clinical results for Barzolvolimab. Analyst sentiment is largely bullish, with strong confidence in the company's future performance. However, the company has a history of failed molecules and no approved products, which has led to some market skepticism in the past. The significant cash burn associated with its clinical-stage operations is also a factor investors consider. The recent appointment of a Chief Commercial Officer in November 2025 indicates a strategic move towards commercialization.

Celldex Therapeutics, Inc. has significant institutional ownership, with 356 institutional owners and shareholders holding a total of 76,339,647 shares as of February 2, 2026, owning approximately 106.44% of the stock. Major institutional owners include Kynam Capital Management, LP, Wellington Management Group LLP, and BlackRock, Inc. The largest individual shareholder is Thomas S. Paluck, owning 7.63 million shares, representing 11.49% of the company. Insiders collectively hold about 19.17% of the stock.